News & Events about Celcuity Inc.
Gedatolisib demonstrated superior anti-proliferative potency and efficacy in endometrial, ovarian and cervical cancer cell lines compared to other PAM inhibitors evaluated regardless of PTEN, P13K, or AKT mutational statusMINNEAPOLIS, MN / ACCESSWIRE / April 18, 2023 / Celcuity Inc. (Nasdaq:CELC...
MINNEAPOLIS, MN / ACCESSWIRE / April 12, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation in the 22nd Annual Needham Virtual Healthcare Conference.Brian Sullivan, Chairman, Chief...
TipRanks Financial Blog
2 months ago
Celcuity (CELC Research Report) received a Buy rating and price target from Craig-Hallum analyst Alexander Nowak on March 21. The companys share... Celcuity (CELC Research Report) received a Buy rating and price target from Craig-Hallum analyst...
MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2022 after the stock market...